Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis
- 17 March 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 73 (3) , 1061-1073
Abstract
Background and Aims: Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes. Approach and Results: We analyzed retrospective data from the Pediatric PSC Consortium. Children treated with OVT were matched 1:1:1 to those treated with UDCA or managed with observation (no treatment) based on the closest propensity score, ensuring similar baseline characteristics. Two hundred sixty‐four patients (88 each with OVT, UDCA, or observation) had matching propensity scores and were similar in demographics, phenotype, immunosuppression, baseline biochemistry, and hepatic fibrosis. After 1 year in an intention‐to‐treat analysis, all outcome metrics were similar regardless of treatment group. In OVT, UDCA, and untreated groups, respectively: Gamma‐glutamyltransferase normalized in 53%, 49%, and 52% (P = not significant [NS]), liver fibrosis stage was improved in 20%, 13%, and 18% and worsened in 11%, 29%, and 18% (P = NS), and the 5‐year probability of liver transplant listing was 21%, 10%, and 12% (P = NS). Favorable outcome was associated with having a mild phenotype of PSC and minimal hepatic fibrosis. Conclusions: We presented the largest‐ever description of outcomes on OVT in PSC and compared them to carefully matched patients on UDCA or no therapy. Neither OVT nor UDCA showed improvement in outcomes compared to a strategy of observation. Patients progressed to end‐stage liver disease at similar rates. Spontaneous normalization of biochemistry is common in children receiving no therapy, particularly in the majority of children with a mild phenotype and an early stage of disease. Placebo‐controlled treatment trials are needed to identify effective treatments for pediatric PSC.Keywords
Funding Information
- PSC Partners Seeking a Cure (2017 Research Grant)
- National Center for Advancing Translational Sciences (8UL1TR000105, KL2TR001065)
This publication has 31 references indexed in Scilit:
- Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitisEuropean Journal of Gastroenterology & Hepatology, 2012
- Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile InfectionClinical Infectious Diseases, 2012
- Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in ChildrenClinical Gastroenterology and Hepatology, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #Hepatology, 2009
- Metronidazole and Ursodeoxycholic Acid for Primary Sclerosing Cholangitis: A Randomized Placebo–Controlled TrialHepatology, 2004
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver diseaseCell, 1993
- Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytesHepatology, 1990
- Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosisHepatology, 1990